14:46 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

MediciNova's tipelukast meets in Phase IIa for liver disease

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) said it will stop early a Phase IIa trial of tipelukast (MN-001) to treat non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) after an interim analysis showed that the product...
16:57 , Apr 2, 2018 |  BC Extra  |  Clinical News

Early stop in liver disease trial boosts MediciNova

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) shares rose Monday on news it will stop early a Phase IIa trial of tipelukast (MN-001) to treat non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) after an interim analysis...
00:41 , Feb 9, 2018 |  BC Innovations  |  Product R&D

R is for readout

While AstraZeneca plc gets credit for transparency in publishing its metrics on R&D productivity, the data cover well-established targets addressed by conventional modalities. The more telling test for its “5R framework” will be whether it...
08:00 , Feb 18, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: 5-lipoxygenase (ALOX5; 5-LO)

Cancer INDICATION: Breast cancer Mouse studies suggest inhibiting ALOX5 could help treat metastatic breast cancer. In a mouse model of spontaneous breast cancer, the generic ALOX5 inhibitor zileuton decreased metastasis to the lung compared with vehicle. In...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

Tipelukast: Phase IIa started

MediciNova began an open-label Phase IIa trial to evaluate 250 mg oral tipelukast given once daily for 4 weeks and then twice daily for 8 additional weeks in about 20 patients ages 21-65. MediciNova has...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

Tipelukast regulatory update

MediciNova said FDA granted Fast Track designation to tipelukast to treat idiopathic pulmonary fibrosis (IPF). MediciNova said the agency approved the protocol for a Phase II trial of the product to treat IPF, but the...
07:00 , Aug 27, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Cyclooxygenase-2 (COX-2); 5-lipoxygenase (ALOX5; 5-LO)

Inflammation INDICATION: Inflammation; pain In vitro and mouse studies suggest an inhibitor of COX-2 and ALOX5 could treat pain and inflammation. Chemical synthesis of barbituric acid analogs followed by testing in COX-2 and ALOX5 assays identified a...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

NPH29: Clinical trial data

A double-blind clinical trial in 21 patients showed that 1% NPH29 cream significantly improved both visual scoring and instrumentally measured L*a*b*L values from baseline to day 30 vs. both vehicle cream and tranexamic acid (p<0.005...
08:00 , Jan 29, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: 5-lipoxygenase activating protein (FLAP; ALOX5AP)

Inflammation INDICATION: Inflammation Studies in vitro and in whole blood identified a new FLAP inhibitor that could help treat inflammation. Chemical synthesis and in vitro screening identified a lead compound called AZD6642 that inhibited FLAP binding activity...
08:00 , Nov 10, 2014 |  BC Week In Review  |  Clinical News

Tipelukast regulatory update

MediciNova said FDA granted Orphan Drug designation to tipelukast to treat idiopathic pulmonary fibrosis (IPF). MediciNova is finalizing a protocol for a Phase II trial of tipelukast for IPF. Tipelukast is a leukotriene receptor antagonist...